Leadership: Page 4


  • Image attribution tooltip

    Permission granted by Mike Rea.

    Image attribution tooltip
    Q&A

    5 minutes with — IDEA Pharma’s Mike Rea

    The CEO on the secrets of innovative pharma companies, his record collection and what he’d always rather be doing.

    By Oct. 11, 2023
  • conference crowd
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Key upcoming events for pharma execs

    Trade shows and events focused on the industry’s hot-button topics, technologies and trends.

    By Oct. 6, 2023
  • digital pill Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Artificial intelligence & machine learning

    After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

    By PharmaVoice staff
  • Emil Kakkis
    Image attribution tooltip

    Permission granted by Dr. Emil Kakkis.

    Image attribution tooltip

    FDA’s ‘ivory tower thinking’ ignores promising biomarkers, says a rare disease CEO

    The FDA wouldn’t review a drug that was 90% effective. In rare diseases, this is too common, said Ultragenyx CEO Dr. Emil Kakkis and a leading rare disease researcher.

    By Oct. 5, 2023
  • Cancer care visionaries, PharmaVoice 100
    Image attribution tooltip

    Photo illustration: Industry Dive; Getty Images

    Image attribution tooltip
    PharmaVoice 100

    PharmaVoice 100s: Cancer care visionaries

    Leaders shaping the future of oncology and cancer care through grit and determination in the face of one of healthcare’s greatest challenges.

    By Oct. 2, 2023
  • PharmaVoice 100 trailblazers
    Image attribution tooltip

    Photo illustration: Industry Dive; Getty Images

    Image attribution tooltip

    The PharmaVoice 100: Trailblazers

    Leaders who are going where no biopharma executive has gone before and changing the industry along the way.

    By Sept. 29, 2023
  • Pfizer CEO Albert Bourla
    Image attribution tooltip
    Drew Angerer via Getty Images
    Image attribution tooltip

    Pfizer CEO Albert Bourla led Big Pharma bonus payouts over 5 years — but he’s no Elon Musk

    A recent report showed how pharma’s bonuses pale in comparison to other industries, but several execs still rake in hefty packages.

    By Sept. 28, 2023
  • Silhouette of people in business attire in front of a wall of windows
    Image attribution tooltip

    Photo illustration: Industry Dive; Getty Images

    Image attribution tooltip
    PharmaVoice 100

    PharmaVoice 100s: Standout execs

    Leaders who’ve created unique strategies for thriving amid the heavy headwinds facing the industry.

    By Sept. 25, 2023
  • Female healthcare worker discussing over medical record with colleagues. Scientists are planning during meeting in laboratory.
    Image attribution tooltip
    Morsa Images via Getty Images
    Image attribution tooltip
    Sponsored by Astellas

    For Astellas’ CMO, accelerating innovation means working at the edge of your comfort zone

    Scientific discovery through new, breakthrough modalities is essential to solve current and future global health challenges – but the path is not easy nor well-defined.

    Sept. 25, 2023
  • PharmaVoice 100 header
    Image attribution tooltip
    Illustration: Deena So Oteh for Industry Dive/PharmaVoice
    Image attribution tooltip

    The 2023 PharmaVoice 100

    This year’s honorees are influential and devoted leaders lifting the pillars of the industry to new heights.

    By Sept. 19, 2023
  • Pharma five-year plan
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Moderna’s bold five-year plan reflects Big Pharma tradition of ‘Will they deliver?’

    Forecasts from the biggest pharma companies follow a pattern of thinking big and manifesting the desired outcome.

    By Sept. 15, 2023
  • leaders hands
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Catching up with 2022 PharmaVoice 100 honorees

    Tapping into our growing community for expertise and inspiration.

    By Sept. 13, 2023
  • Professional headshot of Robert Landry
    Image attribution tooltip
    Permission granted by Regeneron
    Image attribution tooltip

    A tale of two biotechs — 2seventy, Regeneron announce C-suite shakeups

    The biotech’s chief financial officer Robert Landry is retiring in February.

    By Karissa Waddick • Sept. 12, 2023
  • Close up of conference room with glasses of water on the table with papers, armchairs and a large window.
    Image attribution tooltip
    Igor Kutyaev via Getty Images
    Image attribution tooltip

    Ex-Sanofi executive Sibold joins Madrigal as new CEO

    Bill Sibold has led Sanofi's specialty care business unit for the past six years. He replaces Paul Friedman as head of the NASH drug developer.

    By Ned Pagliarulo • Sept. 11, 2023
  • Armon horiztonal
    Image attribution tooltip
    Permission granted by Armon Sharei
    Image attribution tooltip
    Profile

    ‘Not all rainbows and unicorns’ — a former CEO dishes on his rocky biotech ride

    Armon Sharei took his startup SQZ from a graduate project at MIT to a Big Pharma partnership worth $1B+. Despite the company’s stumbles, Sharei’s enthusiasm for biotech’s future remains.

    By Sept. 7, 2023
  • Business person standing in front of window looking at city view.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Pharma faces a slew of leadership shakeups

    Biogen, Sanofi, Bristol Myers Squibb and more have all recently announced major executive changes.

    By Karissa Waddick • Sept. 7, 2023
  • roz Brewer
    Image attribution tooltip

    Permission granted by Roz Brewer

    Image attribution tooltip

    Roz Brewer announces sudden departure as CEO of Walgreens

    The exec who set out to overhaul the long-time pharmacy giant offered few details on why she's stepping down.

    By Sept. 1, 2023
  • Test tube blood
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    ‘We need to do better:’ A biotech CEO on standing apart from the crowd

    The CEO of Cullinan Oncology is taking a small biotech to the next step and believes the temporary financial barriers are smaller than scientific progress.

    By Aug. 29, 2023
  • Shubh Goel, head of immuno-oncology, gastrointestinal tumors franchise, AstraZeneca
    Image attribution tooltip
    Permission granted by AstraZeneca
    Image attribution tooltip

    How an AstraZeneca exec is leading the charge in the next immuno-oncology era

    The pharma giant’s head of immuno-oncology is now charging toward the next step in the cancer fight with long-term survival and precision.

    By Aug. 17, 2023
  • Christy Siegel WoW
    Image attribution tooltip
    Permission granted by Novartis
    Image attribution tooltip
    Podcast

    Woman of the Week: Novartis’ Christy Siegel

    The oncology portfolio general manager for breast and women’s cancers, discusses the company’s recent “landmark” trial and how her family’s history connects her to patients.

    By Taren Grom and Meagan Parrish • Aug. 15, 2023
  • Deborah Dunsire headshot
    Image attribution tooltip
    Permission granted by Lundbeck
    Image attribution tooltip
    Q&A

    5 minutes with — Lundbeck CEO Dr. Deborah Dunsire

    The long-time pharma exec on her most recent wins, her favorite rule to break and the words she lives by.

    By Aug. 11, 2023
  • Weight loss obesity
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    In the era of blockbuster obesity drugs, a personalized approach could boost outcomes

    Ozempic and Wegovy have become household names for weight loss. But obesity is complex, and Phenomix Sciences is looking to bring a personalized medicine approach to the field.

    By Aug. 8, 2023
  • Michael Severino, CEO, Tessera Therapeutics
    Image attribution tooltip
    Permission granted by Tessera
    Image attribution tooltip
    Q&A // Biotech Spotlight

    Why AbbVie’s former president has high hopes for this Flagship-backed biotech

    The CEO of Tessera Therapeutics believes the company’s gene writing technology could eventually cure nearly any genetic disease across patient populations.

    By Karissa Waddick • Aug. 7, 2023
  • Iceberg
    Image attribution tooltip
    Joe Raedle / Staff via Getty Images
    Image attribution tooltip

    New Alzheimer’s treatments are the tip of the iceberg in a long-stymied area of medicine

    A smaller player in the Alzheimer’s space, Prothena is approaching the next phase of treatments, including prevention and clinical trial evolution.

    By Aug. 3, 2023
  • A glass building with a sign that reads,  "Biogen."
    Image attribution tooltip

    Paul Marotta/Sipa USA/Newscom

    Image attribution tooltip

    Biogen’s layoffs are the latest in an industrywide slip

    Over 100 biotech companies so far this year have cut staff due to persistent funding challenges.

    By Karissa Waddick • July 26, 2023
  • Peter Benton
    Image attribution tooltip
    Permission granted by Worldwide Clinical Trials
    Image attribution tooltip
    Q&A

    A leading CRO’s chief exec on why a ‘brave new world’ of clinical research is here

    Peter Benton, co-CEO of Worldwide Clinical Trials, explains how the rise of the mid-sized pharma company has changed drug R&D.  

    By Taren Grom and Meagan Parrish • July 20, 2023